Modern technologies in treatment of diabetes mellitus


Authors: Rid Dravecká
Authors‘ workplace: I. interná klinika LF UPJŠ a UNLP Košice
Published in: Forum Diab 2020; 142(3): 158-168
Category:

Overview

Continuous glucose monitoring (CGM) sensors have made progress in glucose monitoring in type 1 diabetics. The approval of the therapeutic use of CGM has contributed to increased number of CGM users worldwide, which should increase further in the next years as more accurate and cheaper sensors become available. Major CGM companies, such as Dexcom and Medtronic, have announced the development of new devices designed to be smaller and less expensive than current sophisticated systems, which could target not only patients with type 1 diabetes mellitus (DM1) but also people with DM2. The FDA recently defined a new class of CGM devices, i. e. integrated continuous glucose monitoring systems (iCGM), including devices to be used as an integrated system with other compatible devices. The first CGM sensor with FDA approval is the Dexcom G6, launched in 2018. CGM with insulin pump data can improve glucose prediction and automatic basal insulin rate algorithms.

Keywords:

automatic basal insulin rate – continuous glucose monitoring systems – insulin pump


Sources
  1. Villena Gonzales W. Mobashsher AT, Abbosh A. The Progress of Glucose Monitoring. A Review of Invasive to Minimally and Non-Invasive Techniques, Devices and Sensors. Sensors 2019; 19(4): 800. Dostupné z DOI: <http://dx.doi.org/10.3390/s19040800>.
  2. Umpierrez G, Klonoff D. Diabetes Technology Update: Use of Insulin Pumps and Continous Monitoring in the Hospital. Diabetes Care 2018; 41(8): 1579–1589. Dostupné z DOI: <http://dx.doi.org/10.2337/dci18–0002>.
  3. Klonoff D, Ahn D, Drincic A. Continous glucose monitoring: A review of the technology and clinical use. Diabetes Res Clin Pract 2017; 133: 178–192. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2017.08.005>.
  4. Cappon G, Vettoretti M, Sparacino G et al. Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications. Diabetes Metab J 2019; 43(4): 383–397. Dostupné z DOI: <http://dx.doi.org/10.4093/dmj.2019.0121>.
  5. Martin CT, Criego AB, Carlson AL et al. Advanced Technology in the Management of Diabetes: Which Comes First – Continuous Glucose Monitor or Insulin Pump? Curr Diab Rep 2019; 19(8): 50. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892–019–1177–7>.
  6. Lind M et al. Continuous glucose monitoring vs conventional therapy for glycaemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017; 317(4): 379–387. Dostupné z DOI: <http://dx.doi.org10.1001/jama.2016.19976>.
  7. van Beers CA, DeVries JH, Kleijer SJ et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol 2016; 4(11): 893–902. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(16)30193–0>.
  8. Šoupal J, Petruželková L, Flekač M et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimes, in 52 weeks of follow-up: a COMISAR study. Diabetes Technol Ther 2016; 18(9): 532–538. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2016.0171>.
  9. Vesco A, Jedraszko AM, Garza KP et al. Continuous glucose monitoring associated with less diabetes-specific emotional distress and lower A1c among adolescents with type 1 diabetes. J Diabetes Sci Technol 2018; 12(4): 792–799. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296818766381>.
  10. Rodbard D. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycaemic Outcomes. Diabetes Technol Ther. 2017; 19(S3): S25-S37. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2017.0035>.
  11. Dicembrini I, Mannucci E, Monamiet M et al. Impact of technology on glycaemic control in type 2 diabetes: A meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes Obes Metab 2019; 21(12): 2619–2625. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13845>.
  12. Lee H, Hong YJ, Baik S et al. Enzyme-Based Glucose Sensor: From Invasive to Wearable Device. Adv Healthc Mater 2018; 7(8): e1701150. Dostupné z DOI: <http://dx.doi.org/10.1002/adhm.201701150>.
  13. Informácie dostupné z WWW: <https://www.senseonics.com/>.
  14. Shen D, Haojie Yu H, Wang L et al. Recent progress in design and preparation of glucose-responsive insulin delivery systems. J Control Release 2020; 321: 236–258. . Informácie dostupné z DOI: <http://dx.doi.org/10.1016/j.jconrel.2020.02.014>.
  15. Dostupné z WWW: <https://www.freestylelibrepro.com>.
  16. Dostupné z WWW: <https://www.medtronic-diabetes.sk>.
  17. Schaepelynck P, Darmon P, Molines L et al. Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps. Diabetes Metab 2011; 37(Suppl 4): S85-S93. Dostupné z DOI: <http://dx.doi.org/10.1016/S1262–3636(11)70972–7>.
  18. Vettoretti M, Facchinetti A. Combining continuous glucose monitoring and insulin pumps to automatically tune the basal insulin infusion in diabetes therapy: a review. Biomed Eng Online 2019; 18(1): 37. Dostupné z DOI: <http://dx.doi.org/10.1186/s12938–019–0658-x>.
  19. Dadlani V, Pinsker JE, Dassau E et al. Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes. Cur Diab Rep 2018; 18(10): 88. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892–018–1051-z>.
  20. Lepore G, Scaranna C, Corsi A et al. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study. Diabetes Technol Ther 2020; 22(4): 321–325. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2019.0302>.
  21. Stone M, Agrawal P, Chen X et al. Retrospective analysis of 3-month real-world glucose data after the MiniMed 670G system commercial launch. Diabetes Technol Ther 2018; 20(10): 689–692. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2018.0202>.
  22. News from Medtronic: Hypoglycemia Prediction (IQcast) with Sugar.IQ and Timing on the Next-Gen MiniMed 780G Closed Loop. Kwon J, Brown A. Dostupné z WWW: <https://diatribe.org/news-medtronic-hypoglycemia-prediction-iqcast-sugariq-and-timing-next-gen-minimed-780g-closed-loop>.
  23. Brown S, Raghinaru D, Emory E et al. First Look at Control-IQ: A New-Generation Automated Insulin Delivery System. Diabetes Care 2018; 41(12): 2634–2636. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18–1249>.
  24. Lewis D, Leibrand S. [#OpenAPS Community]. Real-world use of open source artificial pancreas systems. J Diabetes Sci Technol 2016; 10(6): 1411. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296816665635>.
  25. Litchman M, Lewis D, Kelly LA et al. Twitter analysis of #OpenAPS DIY artificial pancreas technology use suggests improved A1C and quality of life. J Diabetes Sci Technol 2019; 13(2): 164–170. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296818795705>.
Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account